Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Torino

Showing results (1-10 of 87) with videos related to

Pageof 9
Sort By:
Current Pharmaceutical Design|March 14, 2007
Targeted therapy of breast cancerRaffaele Longo, Francesco Torino, Giampietro Gasparini
Critical Reviews in Oncology/Hematology|March 13, 2013
The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancerFrancesco Torino, Roberta Sarmiento, Giampietro Gasparini
Current Opinion in Oncology|May 3, 2016
Endocrinological side-effects of immune checkpoint inhibitorsFrancesco Torino, Salvatore M Corsello, Roberto Salvatori
Endocrinology and Metabolism Clinics of North America|October 23, 2025
Hypophysitis Associated with Immune Checkpoint InhibitorsAndrea Corsello, Rosa Maria Paragliola, Francesco Torino, et al.
Critical Reviews in Oncology/Hematology|August 13, 2021
A scoping review on the "burned out" or "burnt out" testicular cancer: When a rare phenomenon deserves more attentionGiovanni Maria Iannantuono, Lidia Strigari, Mario Roselli, et al.
Cancer Journal (Sudbury, Mass.)|August 2, 2005
Tailored therapy of colorectal cancer: results, challenges and future directionsGiampietro Gasparini, Raffaele Longo, Francesco Torino, et al.
Professioni Infermieristiche|November 14, 2014
[Mutuality in caregiving: a literature review]Silvio Simeone, Serenella Savini, Francesco Torino, et al.
International Journal of Molecular Sciences|April 12, 2022
Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic ReviewGiovanni Maria Iannantuono, Silvia Riondino, Stefano Sganga, et al.
Thyroid : Official Journal of the American Thyroid Association|May 7, 2009
Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?Francesco Torino, Salvatore Maria Corsello, Raffaele Longo, et al.
Nature Reviews. Clinical Oncology|April 1, 2009
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapyFrancesco Torino, Salvatore Maria Corsello, Raffaele Longo, et al.
Pageof 9

Showing results (1-10 of 87) with videos related to

Sort By:
Pageof 9
Current Pharmaceutical Design|March 14, 2007
Targeted therapy of breast cancerRaffaele Longo, Francesco Torino, Giampietro Gasparini
Critical Reviews in Oncology/Hematology|March 13, 2013
The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancerFrancesco Torino, Roberta Sarmiento, Giampietro Gasparini
Current Opinion in Oncology|May 3, 2016
Endocrinological side-effects of immune checkpoint inhibitorsFrancesco Torino, Salvatore M Corsello, Roberto Salvatori
Endocrinology and Metabolism Clinics of North America|October 23, 2025
Hypophysitis Associated with Immune Checkpoint InhibitorsAndrea Corsello, Rosa Maria Paragliola, Francesco Torino, et al.
Critical Reviews in Oncology/Hematology|August 13, 2021
A scoping review on the "burned out" or "burnt out" testicular cancer: When a rare phenomenon deserves more attentionGiovanni Maria Iannantuono, Lidia Strigari, Mario Roselli, et al.
Cancer Journal (Sudbury, Mass.)|August 2, 2005
Tailored therapy of colorectal cancer: results, challenges and future directionsGiampietro Gasparini, Raffaele Longo, Francesco Torino, et al.
Professioni Infermieristiche|November 14, 2014
[Mutuality in caregiving: a literature review]Silvio Simeone, Serenella Savini, Francesco Torino, et al.
International Journal of Molecular Sciences|April 12, 2022
Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic ReviewGiovanni Maria Iannantuono, Silvia Riondino, Stefano Sganga, et al.
Thyroid : Official Journal of the American Thyroid Association|May 7, 2009
Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?Francesco Torino, Salvatore Maria Corsello, Raffaele Longo, et al.
Nature Reviews. Clinical Oncology|April 1, 2009
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapyFrancesco Torino, Salvatore Maria Corsello, Raffaele Longo, et al.
Pageof 9